RBC Capital initiated coverage on Intra-Cellular Therapies (NASDAQ: ITCI) with a Outperform rating and a price target of $41. Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE